Cargando…

A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma

BACKGROUND: There is clinical evidence to suggest that tumour necrosis factor-α (TNF-α) may be a therapeutic target in renal cell carcinoma (RCC). Multi-targeted kinase inhibitors, such as sorafenib and sunitinib, have become standard of care in advanced RCC. The anti-TNF-α monoclonal antibody infli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Larkin, J M G, Ferguson, T R, Pickering, L M, Edmonds, K, James, M G, Thomas, K, Banerji, U, Berns, B, de Boer, C, Gore, M E
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2010
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2967062/ https://www.ncbi.nlm.nih.gov/pubmed/20842130 http://dx.doi.org/10.1038/sj.bjc.6605889

Ejemplares similares

Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies
por: Eisen, T, et al.
Publicado: (2011)

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis
por: Eisen, T, et al.
Publicado: (2006)

A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma
por: Larkin, J M G, et al.
Publicado: (2007)

A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas
por: Lee, J K, et al.
Publicado: (2013)

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer
por: Rossi, J-F, et al.
Publicado: (2010)

A Phase I Study of High-Dose Interleukin-2 With Sorafenib in Patients With Metastatic Renal Cell Carcinoma and Melanoma
por: Monk, Paul, et al.
Publicado: (2014)

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial
por: Bengala, C, et al.
Publicado: (2010)

Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial
por: Procopio, G, et al.
Publicado: (2011)

Renal cell carcinoma and the use of sorafenib
por: Larkin, James MG, et al.
Publicado: (2006)

Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
por: Hottinger, A F, et al.
Publicado: (2014)

Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
por: Nabhan, C, et al.
Publicado: (2012)

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
por: Samalin, E, et al.
Publicado: (2014)

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib
por: El Dika, Imane, et al.
Publicado: (2020)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
por: Escudier, B, et al.
Publicado: (2014)

A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer
por: Desar, I M E, et al.
Publicado: (2010)

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents
por: Moreno Garcia, V, et al.
Publicado: (2012)

Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma
por: DuBois, S G, et al.
Publicado: (2015)

Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study
por: Mouriaux, F, et al.
Publicado: (2016)

Infliximab in the treatment of patients with severe COVID-19 (INFLIXCOVID): protocol for a randomised, controlled, multicentre, open-label phase II clinical study
por: Coldewey, Sina M., et al.
Publicado: (2022)

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours
por: Khan, O A, et al.
Publicado: (2011)

Phase I trial outcomes in older patients with advanced solid tumours
por: Khan, K H, et al.
Publicado: (2016)

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
por: Ikeda, M., et al.
Publicado: (2016)

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial
por: Cella, D, et al.
Publicado: (2013)

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials
por: Basu, B., et al.
Publicado: (2012)

Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part
por: Vermorken, J B, et al.
Publicado: (2011)

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer
por: Huijts, Charlotte M, et al.
Publicado: (2011)

Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib
por: Flaig, T W, et al.
Publicado: (2010)

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
por: Syversen, Silje W, et al.
Publicado: (2020)

Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease
por: Yau, Thomas, et al.
Publicado: (2012)

Combination chemotherapy with carboplatin, capecitabine and epirubicin (ECarboX) as second- or third-line treatment in patients with relapsed ovarian cancer: a phase I/II trial
por: Rothermundt, C, et al.
Publicado: (2006)

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2008)

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
por: Bernhardt, S L, et al.
Publicado: (2006)

Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
por: Inokuchi, M, et al.
Publicado: (2006)

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
por: Steinbild, S, et al.
Publicado: (2007)

Complications of hyperglycaemia with PI3K–AKT–mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials
por: Geuna, E, et al.
Publicado: (2015)

Phase I/II study of verteporfin photodynamic therapy in locally advanced pancreatic cancer
por: Huggett, M T, et al.
Publicado: (2014)

Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I/II study
por: Klautke, G, et al.
Publicado: (2006)

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
por: Postel-Vinay, S, et al.
Publicado: (2009)

Phase I study of pemetrexed with sorafenib in advanced solid tumors
por: Poklepovic, Andrew, et al.
Publicado: (2016)

Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn’s disease
por: Oh, Eun Hye, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_prlnk4fca4r5ium536g9frp7j3